Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,179 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis.
Kabaçam G, Dalekos GN, Çakaloğlu Y, Zachou K, Bock T, Erhardt A, Zeuzem S, Tabak F, Yalçin K, Bozdayi AM, Dienes HP, Bozkaya H, Manns M, Wedemeyer H, Yurdaydin C. Kabaçam G, et al. Among authors: zeuzem s. Turk J Gastroenterol. 2012;23(5):560-8. doi: 10.4318/tjg.2012.0538. Turk J Gastroenterol. 2012. PMID: 23161302 Free article. Clinical Trial.
Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C.
Rasenack J, Zeuzem S, Feinman SV, Heathcote EJ, Manns M, Yoshida EM, Swain MG, Gane E, Diago M, Revicki DA, Lin A, Wintfeld N, Green J. Rasenack J, et al. Among authors: zeuzem s. Pharmacoeconomics. 2003;21(5):341-9. doi: 10.2165/00019053-200321050-00005. Pharmacoeconomics. 2003. PMID: 12627987 Clinical Trial.
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.
Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, Niesters HG, Zondervan P, Hansen B, Schalm SW; HBV 99-01 Study Group; Rotterdam Foundation for Liver Research. Janssen HL, et al. Among authors: zeuzem s. Lancet. 2005 Jan 8-14;365(9454):123-9. doi: 10.1016/S0140-6736(05)17701-0. Lancet. 2005. PMID: 15639293 Clinical Trial.
The way forward in HCV treatment--finding the right path.
Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M. Manns MP, et al. Among authors: zeuzem s. Nat Rev Drug Discov. 2007 Dec;6(12):991-1000. doi: 10.1038/nrd2411. Nat Rev Drug Discov. 2007. PMID: 18049473 Review.
The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection.
Potthoff A, Wedemeyer H, Boecher WO, Berg T, Zeuzem S, Arnold J, Spengler U, Gruengreiff K, Kaeser T, Schuchmann M, Bergk A, Forestier N, Deterding K, Manns MP, Trautwein C; Hep-Net B/C Co-infection Study Group. Potthoff A, et al. Among authors: zeuzem s. J Hepatol. 2008 Nov;49(5):688-94. doi: 10.1016/j.jhep.2008.03.028. Epub 2008 Apr 29. J Hepatol. 2008. PMID: 18490077 Clinical Trial.
1,179 results